We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+21.62%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$135M
AUM Growth
+$7.99M
Cap. Flow
+$4.82M
Cap. Flow %
3.56%
Top 10 Hldgs %
69.24%
Holding
34
New
11
Increased
8
Reduced
6
Closed
4

Top Buys

Rank Stock Value
1
TVTX icon
Travere Therapeutics
TVTX
+$17.7M
2
CMRX
Chimerix, Inc.
CMRX
+$10.8M
3
GNMK
GenMark Diagnostics, Inc
GNMK
+$5.41M
4
BIND
BIND THERAPEUTICS INC
BIND
+$3.55M
5
EPZM
Epizyme, Inc
EPZM
+$3.5M

Top Sells

Rank Stock Value
1
GENT
GENTIUM SPA ADS
GENT
+$29.2M
2
GERN icon
Geron
GERN
+$6.5M
3
LGND icon
Ligand Pharmaceuticals
LGND
+$3.67M
4
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$3.64M
5
NPSP
NPS PHARMACEUTICALS INC
NPSP
+$1.9M

Sector Composition

Rank Sector Weight
1 Healthcare 80.23%
2 Miscellaneous 19.77%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CPXX
26
DELISTED
CELATOR PHARMACEUTICALS INC. COMMON STOCK
CPXX
$1.03M 0.76%
325,000
+15,000
+5% +$50.8K
MGNX icon
27
MacroGenics
MGNX
$260M
$838K 0.62%
+30,000
New +$1.06M
AFFX
28
DELISTED
Affymetrix Inc
AFFX
$713K 0.53%
+100,000
New +$806K
KIPS
29
DELISTED
KIPS BAY MEDICAL INC
KIPS
$540K 0.4%
+777,531
New +$572K
NUWE icon
30
Nuwellis
NUWE
$3.14M
– –
0
– –
ICPT
31
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
– –
-56,900
Closed -$3.64M
INFI
32
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
– –
-130,000
Closed -$1.67M
GENT
33
DELISTED
GENTIUM SPA ADS
GENT
– –
-505,000
Closed -$29.2M
MDVN
34
DELISTED
MEDIVATION, INC.
MDVN
– –
-50,000
Closed -$1.6M
1
2

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q1 2014 Portfolio in Review

As of Q1 2014, Opaleye Management held 34 positions worth $135M, up 6.3% from $127M the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Opaleye Management deployed $4.82M of net new capital in Q1 2014, opening 11 new positions and adding to 8 existing holdings. Its largest new stake was Travere Therapeutics: 1,153,230 shares worth $24.4M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, up from 56% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Geron, an estimated $6.5M trimmed.

  • Opaleye Management's largest Q1 2014 buy was Travere Therapeutics: 1,153,230 shares worth $24.4M.
  • Opaleye Management added most to BIND THERAPEUTICS INC in Q1 2014, an estimated $3.55M increase.
  • Opaleye Management's biggest Q1 2014 reduction was Geron, cutting an estimated $6.5M.
  • Opaleye Management fully exited GENTIUM SPA ADS in Q1 2014, selling an estimated $29.2M.
  • Opaleye Management's ten largest holdings make up 69% of its $135M portfolio in Q1 2014.
  • Opaleye Management opened 11 new positions and closed 4 in Q1 2014.
  • Opaleye Management's portfolio value rose 6.3% quarter-over-quarter to $135M.

Based on Opaleye Management's 13F filing for Q1 2014, filed 15 May 2014.